亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

濟南偉都醫藥化工科技有限公司  

大陸,港澳臺,北美,南美,東歐,西歐,東南亞,全球

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:楊女士
  • 電話:0531-88682202
  • 郵件:wedochem03@163.com
  • 傳真:0531-88873470
  • QQ:1158262190
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 吉西他賓鹽酸鹽 122111-03-9
吉西他賓鹽酸鹽 122111-03-9
單價 20.00 / 公斤對比
銷量 暫無
發貨 山東濟南市付款后3天內
庫存 100公斤起訂1公斤
品牌 偉都
型號 吉西他賓鹽酸鹽 122111-03-9
規格 吉西他賓鹽酸鹽 122111-03-9
過期 長期有效
更新 2013-03-07 08:33
 
詳細信息

吉西他賓鹽酸鹽 122111-03-9

英文名  Gemcitabine hydrochloride
別名  4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-pyrimidin-2-one hydrochloride
產品名稱  鹽酸吉西他濱; 吉西他賓鹽酸鹽; 4-氨基-1-(3,3-二氟-4-羥基-5-羥甲基四氫呋喃-2-基)-1H-嘧啶-2-酮鹽酸鹽

分子式  C9H11F2N3O4.HCl
分子量  299.66
CAS 登錄號  122111-03-9

 

©2025 濟南偉都醫藥化工科技有限公司 版權所有   技術支持:化工網   訪問量:38150  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |